腾盛博药在EASL会议上公布ENSURE 2期研究数据
5月8日，腾盛博药-B（02137）发布公告，公司在2025年欧洲肝病研究协会(EASL)会议上公布了其ENSURE 2期研究的最新数据。
该研究旨在评估elebsiran与聚乙二醇干扰素α联合治疗慢性乙型肝炎病毒感染者的效果。研究显示，在治疗结束时，61%的抗HBs应答者实现了HBsAg清除，而无应答者仅为10%。此外，经过BRII-179预治疗的参与者在HBsAg清除方面表现出更显著的优势，第24周时，83%的BRII-179经治参与者达到了HBsAg清除。
该研究的结果表明，elebsiran与PEG-IFNα联合治疗24周后均可实现更高的HBsAg清除率，且在治疗效果上优于单药治疗。公司首席医学官David Margolis表示，研究数据令人鼓舞，未来将继续推进临床研究，为慢性乙型肝炎患者提供有效的治疗选择。公司还计划在未来几个月内，在多个科学会议上分享关键数据。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10